Summary of DocGo FY Conference Call Company Overview - **Company**: DocGo (NasdaqCM:DCGO) - **Business Model**: A tech-driven provider of mobile health services, focusing on non-emergency medical transportation and various mobile health services including care gap closures, mobile phlebotomy, and remote patient monitoring, primarily for cardiac patients - **Operations**: Operates a fleet of approximately 900 vehicles and employs around 3,000 healthcare professionals, providing services across 50 states and the U.K. [5][6] Macro Environment and Regulatory Concerns - **Regulatory Shifts**: Ongoing discussions regarding Medicaid eligibility and administration could impact the care gap closure business if fewer individuals are covered [8][9] - **Demand Pressure**: A potential reduction in Medicaid coverage may increase demand for mobile health services as the existing healthcare system is already under pressure [9] - **AI Integration**: DocGo is leveraging AI to enhance efficiency in patient outreach and clinician operations [10] Business Segments and Growth Opportunities - **Revenue Segmentation**: Revenue is derived from two main segments: medical transportation (70% of revenue) and mobile health services, with the latter expected to grow rapidly [15][16] - **Care Gap Closure Business**: Currently working with six payers, with a cumulative assignment of 1.3 million lives. Revenue from this segment has quadrupled from 2024 to 2025, although it has lower margins compared to other mobile health services [18][19] - **Growth Focus**: The company is prioritizing investments in mobile health lines, particularly care gap closures and mobile phlebotomy, which are expected to yield higher margins in the future [19][20] Staffing and Operational Challenges - **Staffing Issues**: In 2025, DocGo had to outsource 26,000 transports due to staffing shortages, resulting in an estimated opportunity cost of $8-$9 million in revenue [40][41] - **Retention Strategies**: The company is focusing on improving recruitment and retention of EMTs and paramedics, which are critical to operations [42][49] - **Capacity Utilization**: The company aims to maintain a capacity utilization rate of 0.35 to 0.4 trips per 10-hour shift to optimize operations [45][48] Financial Guidance and M&A Strategy - **Revenue Guidance**: Projected revenue for 2026 is between $280 million and $300 million, reflecting organic growth without accounting for new contracts or M&A [54][55] - **M&A Opportunities**: DocGo is looking for tuck-in acquisitions to enhance mobile health capabilities and bolster operations in existing markets. The current market conditions present favorable opportunities for acquisitions [56][60] - **Balance Sheet Management**: The company has a solid balance sheet but is cautious about using equity for acquisitions. Recent cash collections from previous contracts are expected to support ongoing operations [61][62] Government Relations and Future Outlook - **Government Contracts**: The company is cautious about engaging in new government contracts due to working capital intensity but sees potential in population health programs under the new administration [63][66] - **Guidance Approach**: The company aims to provide conservative guidance to ensure that it can meet expectations without relying on uncertain factors [68][74] Conclusion DocGo is positioned to capitalize on growth opportunities in mobile health services while navigating regulatory challenges and operational hurdles. The focus on improving staffing, leveraging technology, and pursuing strategic acquisitions will be critical for achieving its financial targets in the coming years.

Summary of DocGo Conference Call Company Overview - **Company Name**: DocGo - **Industry**: Mobile health and medical transportation services - **Stock Symbol**: DCGO (NASDAQ) - **Geographic Presence**: United States and United Kingdom - **Core Services**: Medical transportation, care in the home, remote patient monitoring, and technology-driven mobile healthcare solutions [1][2][3] Key Points and Arguments Business Model and Services - DocGo operates a tech-driven mobile health platform that includes ambulance services, medical transportation management, and home care services [2][4] - The company aims to deliver healthcare at any address, providing a turnkey solution for hospitals and facilities that prefer to outsource their transportation needs [4][5] - The use of "upskilled clinicians" allows for more efficient care delivery, utilizing qualified personnel for tasks that are often performed by overqualified individuals [5][6] Financial Performance - In 2023, DocGo's revenues peaked at over $600 million, largely due to non-recurring revenue from migrant-related services [15] - Projected revenue for 2025 is approximately $320 million, indicating a significant drop due to the transition away from non-core services [15] - Core medical transportation revenue has grown from $48 million in 2019 to over $200 million in 2023, demonstrating steady growth despite overall revenue fluctuations [16] Recent Developments - The acquisition of SteadyMD enhances DocGo's telehealth capabilities and expands its virtual care network across all 50 states [10][11] - The company has a strong balance sheet, with a cash balance of approximately $95 million and a focus on both organic and inorganic growth strategies [20][46] Market Position and Strategy - DocGo operates in a fragmented market with over 10,000 ambulance providers in the U.S., positioning itself as a scalable solution provider [37] - The company emphasizes vertical integration and a competitive technology advantage, which are critical for maintaining its market position [47][40] - Partnerships with health plan providers allow DocGo to reach patients who are delinquent in receiving necessary care, thereby increasing access and reducing overall healthcare costs [32][25] Challenges and Future Outlook - The company faces challenges related to accounts receivable, particularly from municipal contracts, but has successfully collected 96% of outstanding invoices [49] - The new mayoral administration in New York City may present both opportunities and risks, but DocGo's existing contracts with health and hospital systems are expected to continue [50][51] - The focus remains on closing care gaps and providing efficient healthcare solutions to prevent hospital readmissions and manage chronic diseases [22][24] Additional Important Information - DocGo's mobile health segment is expected to conduct over 150,000 home visits in 2025, reflecting the growing demand for home-based healthcare services [28] - The company is actively looking for acquisition opportunities in the healthcare sector, viewing current market conditions as favorable for growth [44][45] - Leadership includes experienced professionals from both healthcare and general management backgrounds, contributing to a well-rounded management team [47][39]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $70.8 million, down from $138.7 million in Q3 2024, primarily due to the sunset of migrant-related projects [22] - Excluding migrant-related programs, revenue increased by 8% to $62.4 million in Q3 2025 from $58 million in Q3 2024 [22] - Adjusted EBITDA for Q3 2025 was a loss of $7.1 million compared to an Adjusted EBITDA of $17.9 million in Q3 2024 [23] - Adjusted gross margin was 33% in Q3 2025, down from 36% in Q3 2024 [24] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.1 million in Q3 2025 from $48 million in Q3 2024, driven by gains in nearly all U.S. markets [23] - Mobile health revenue for Q3 2025 was $20.7 million, down from $90.7 million in Q3 2024, with non-migrant mobile health revenues increasing by over 20% year-over-year [23] - The payer and provider vertical is expected to generate approximately $50 million in revenue in 2025, growing to $85 million in 2026, including $25 million from the SteadyMD acquisition [11][12] Market Data and Key Metrics Changes - The medical transportation business is expected to generate more than $200 million in revenue in 2025, with a projected Adjusted EBITDA contribution margin of approximately 12% [9] - Remote patient monitoring is operating at an annual run rate of approximately $15 million, with a greater than 10% Adjusted EBITDA contribution margin [12] Company Strategy and Development Direction - The company aims to build a robust, evergreen healthcare business and has a vision of bringing the capabilities of a doctor's office into a patient's living room [7][21] - The acquisition of SteadyMD is expected to enhance the company's virtual care capabilities and expand its clinical capacity [16][17] - The company plans to remain active in M&A to acquire traditional healthcare assets that can benefit from its technology and mobile health capabilities [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive substantial value amid increasing healthcare costs and operational challenges [14] - The company anticipates a gradual abatement of investments in early-stage business lines over the course of 2026, aiming for profitability [19] - Management expects to exit 2026 with a cash balance of about $65 million, which will be the low point subject to buybacks or additional acquisitions [30] Other Important Information - The company has improved its balance sheet by paying off $30 million in debt and is now debt-free for the first time since late 2023 [27] - The company has collected approximately 96% of all migrant-related receivables from the inception of those programs [29] Q&A Session Summary Question: Can you help bridge the implied margins for the fourth quarter? - Management indicated that SteadyMD will contribute slightly to Q4 margins but will not have a material impact [33] Question: How does the EBITDA guidance for 2026 improve throughout the year? - Management expects the bulk of negative EBITDA will come in the first half of 2026, with improvements in the second half [37] Question: What is the expected revenue breakdown for 2026? - Management stated that there will be no migrant-related revenues for 2026, with a breakdown of about two-thirds transport and one-third mobile health [39] Question: Can you provide insights on payer-provider revenue growth? - Management confirmed that the $85 million for payer and provider in 2026 includes $25 million from SteadyMD and does not account for new deal closures [44] Question: What is the current view of the hospital spending environment? - Management noted that hospitals are cautious with budgets but are receptive to solutions that help lower costs and improve efficiency [66][69]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $70.8 million, down from $138.7 million in Q3 2024, primarily due to the sunset of migrant-related projects [21] - Excluding migrant-related revenue, revenue increased by 8% to $62.4 million in Q3 2025 from $58 million in Q3 2024 [21] - Adjusted EBITDA for Q3 2025 was a loss of $7.1 million compared to adjusted EBITDA of $17.9 million in Q3 2024 [22] - Adjusted gross margin was 33% in Q3 2025, down from 36% in Q3 2024 [23] Business Line Data and Key Metrics Changes - Medical transportation services revenue increased to $50.1 million in Q3 2025 from $48 million in Q3 2024, driven by gains in nearly all U.S. markets [22] - Mobile health revenue for Q3 2025 was $20.7 million, down from $90.7 million in Q3 2024, with non-migrant mobile health revenues increasing by over 20% year-over-year [22] - Remote patient monitoring is operating at an annual run rate of approximately $15 million, with a greater than 10% adjusted EBITDA contribution margin [12] Market Data and Key Metrics Changes - The medical transportation business is expected to generate more than $200 million of revenue in 2025, indicating strong foundational asset growth [9] - The payer and provider vertical is expected to generate approximately $50 million of revenue in 2025, growing to $85 million in 2026, including $25 million from the SteadyMD acquisition [11][30] Company Strategy and Development Direction - The company aims to build a robust, evergreen healthcare business and has a vision of bringing the capabilities of a doctor's office into a patient's living room [6][21] - The acquisition of SteadyMD is expected to enhance the company's virtual care network and clinical capacity, allowing for more efficient patient care delivery [17][18] - The company plans to remain active in M&A to acquire traditional healthcare assets that can benefit from its technology and mobile health capabilities [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive substantial value amid increasing healthcare costs and operational challenges [14] - The company expects to exit 2026 with a cash balance of about $65 million, indicating a positive outlook despite anticipated losses in the first half of the year [30][28] - Management highlighted the importance of their services in helping hospitals manage patient flow and reduce costs, which is timely given current market conditions [46][50] Other Important Information - The company has made significant progress in reducing its debt, paying off $30 million in credit line debt during Q3 2025 [26] - The adjusted gross margin for the medical transportation segment was 31.7% in Q3 2025, the highest since Q1 2024 [23] Q&A Session Summary Question: Can you help bridge the implied margins for the fourth quarter? - Management indicated that SteadyMD's contribution would be around $5 million in revenue for the quarter, slightly EBITDA negative, impacting margin percentages [31] Question: How does the EBITDA guidance for 2026 improve throughout the year? - Management expects the bulk of the negative EBITDA to occur in the first half of 2026, with improvements in gross margins and reduced SG&A expenses anticipated in the latter half [34] Question: What is the expected revenue growth for the payer-provider segment? - The payer-provider revenue for 2026 includes $25 million from SteadyMD, with the remaining $60 million from the current baseline business, not accounting for new contracts or M&A [36] Question: How does the company balance supply and demand in transportation? - Management noted that they are basing hiring plans on the number of trips currently being outsourced, estimating a need for about 700-800 additional staff to meet demand [43] Question: What is the current view on the hospital spending environment? - Management acknowledged concerns about hospital budgets but emphasized their focus on helping hospitals save money and improve efficiency [46][50]

Summary of the Conference Call Company and Industry Overview - The conference is part of the 23rd annual Morgan Stanley Healthcare Conference, focusing on the healthcare industry and innovations in home-based care [2][3] - The company discussed is DocGo, a medical transportation and mobile health provider, which has been innovating in the medical transportation space for over 10 years [4][5] Key Points and Arguments Mobile Health Growth - DocGo has seen significant growth in the mobile health segment, particularly in coordinating care for high-utilizing members through partnerships with insurance companies [4][5] - The company has expanded its reach from serving 2,000 patients to nearly a million patients across the New York tri-state area and California [6][8] - On average, DocGo closes almost two care gaps per home visit, with some visits closing up to six gaps [6][8] Technology Integration - The tech stack developed by DocGo is crucial for efficient home-based medical care, allowing licensed practical nurses (LPNs) and medical assistants to provide care under the direction of primary care providers [10][11] - Integration with electronic health record (EHR) systems like Epic enhances coordination and efficiency in patient care [11] Revenue and Contract Stability - DocGo's contracts in the transportation segment typically last three to five years and are described as "sticky," indicating high customer retention [13][14] - The company is transitioning from episodic contracts with municipal governments to more sustainable, population health-focused contracts with payers [15] Labor and Inflation Management - Staffing is a significant challenge, with 800 open roles to fill, but the company maintains a strong reputation as a desirable workplace [16][18] - Inflationary pressures are minimal, with fuel costs decreasing and existing vehicles owned or procured under favorable terms [17] Payer Opportunities - DocGo works primarily with managed care, Medicaid, and Medicare Advantage plans, focusing on the dual special needs population, which shows higher engagement rates [20][21] - The company aims to keep patients out of hospitals, aligning with value-based care models that incentivize health plans to manage costs effectively [23][24] M&A Strategy - DocGo is looking for M&A opportunities that add capabilities or expand geographic reach, particularly in underserved areas [26][27] - The medical transportation market is estimated at $10 billion, with DocGo currently capturing around $225 million, indicating significant growth potential [49] Capital Allocation - The company prioritizes organic growth, staff training, and M&A opportunities while maintaining a strong balance sheet with over $100 million in cash [30][32][33] Market Expansion - DocGo expands into new markets based on demand from existing customers, ensuring they have anchor clients before entering new regions [37][38] Go-to-Market Strategy - The sales cycle for new customers can range from 6 to 18 months, with existing customers typically resulting in faster expansions [42][43] Telehealth Perspective - While telehealth is recognized as a valuable service, DocGo emphasizes the necessity of in-person care for certain medical needs, positioning itself uniquely in the market [54][56] Other Important Insights - The company has a high Net Promoter Score of over 90, indicating strong patient satisfaction [47][48] - The medical transportation segment is increasingly recognized as vital for patient flow management within hospital systems [51][52]

Summary of Strata Critical Medical (BLDE) Conference Call Company Overview - **Company Name**: Strata Critical Medical (formerly Blade Urban Air Mobility) [3] - **Industry**: Medical logistics, specifically organ transportation [4][5] Key Transaction Details - **Divestiture**: Agreement with Joby Aviation to sell the passenger business for up to $125 million, receiving approximately $80 million in stock upfront [3][4] - **Future Collaboration**: Long-term arrangement with Joby to use their electric aircraft for medical purposes, expected to be quieter and lower cost [4] Business Focus and Growth - **Core Business**: Focus on medical logistics, specifically transporting human organs for transplant, which grew nearly 20% in the last quarter [4][6] - **Market Dynamics**: New regulations and technology are increasing the number of viable organ transplants, with a mid to high single-digit growth in organ transplants expected [8][10] - **Operational Model**: Utilizes an asset-light network, with two-thirds of flights on aircraft not owned by the company, allowing for flexibility and cost savings [5][6] Market Opportunities - **Regulatory Changes**: Shift in government policy prioritizing organ matching based on need rather than geographic convenience, benefiting logistics providers [6][10] - **Technological Advancements**: Introduction of perfusion technology allows for the use of previously unsuitable organs, enhancing transplant viability [8][10] - **Expansion Plans**: Building a ground network and expanding service offerings, including administrative and clinical support for organ matching [11][12] Financial Outlook - **Profitability**: The divestiture is expected to be profit neutral, with anticipated corporate savings of $7 million starting Q4 [14][15] - **Growth Projections**: Mid-teens growth expected for the remainder of the year, with potential for acceleration due to increased complexity in organ logistics [36][40] - **Margin Improvement**: Targeting a segment adjusted EBITDA margin increase from 13% to the high teens through operational efficiencies and cost structure optimization [48][51] Competitive Landscape - **Market Share**: Holds approximately 30% market share in air logistics, with significant opportunities in ancillary services [31][40] - **Fragmented Industry**: Competes against numerous small operators, allowing Strata to leverage its national network for flexibility and efficiency [31][33] Strategic Partnerships - **Collaboration with Organox**: Aims to pre-position perfusion devices at aviation hubs, enhancing service offerings and customer satisfaction [41][42] Key Takeaways for Investors 1. **Growing Market**: Attractive growth potential in the organ transportation sector with evolving regulations and technology [52] 2. **Unique Positioning**: Ability to build new capabilities that customers currently source from competitors [52] 3. **Capital Allocation**: Strong potential for strategic acquisitions and investments in the logistics space [53]

Summary of DocGo (DCGO) FY Conference Call - August 26, 2025 Company Overview - **Company Name**: DocGo (DCGO) - **Industry**: Mobile health services and integrated medical mobility solutions - **Core Business**: Provides last mile mobile health services, medical transport, and care in the home [1][4] Key Points and Arguments Investment Thesis - DocGo is positioned as a leading provider of tech-driven mobile care, with a strong balance sheet and a large total addressable market (TAM) [4][6] - The company aims to deliver healthcare at any address, moving care outside traditional hospital settings [6][7] Business Segments - **Medical Transport**: The foundation of the business, expanding with a focus on non-emergency medical transport [5][43] - **Mobile Health**: Rapidly growing segment providing care in the home, with a broad range of services [5][31] Financial Performance - Revenue for Q2 was approximately $80.4 million, slightly above consensus, with a gross margin of 31.5% [16] - The company has collected about 98% of receivables from New York City and State for migrant services, improving cash flow [14][15] - Book value per share is increasing, and the company is trading at a significant discount to its book value [12][13] Market Dynamics - The U.S. healthcare system spends significantly on treating chronic diseases, with 90% of $4.5 trillion spent on chronic conditions and mental health [21][22] - DocGo aims to assist payers and providers in preventing chronic issues by offering tailored solutions [22][23] Growth Opportunities - The number of patients assigned for care gap closure is projected to exceed 1 million, with a significant increase in completed visits expected [53][54] - The company is focusing on expanding partnerships with health plans and hospital systems to enhance service delivery [62] Competitive Advantages - DocGo has a proprietary logistics platform that allows efficient routing and service delivery, creating a competitive moat [34][60] - The company has vertical integration, combining technology, staffing, and clinical services, which is rare in the industry [58][65] Management and Strategy - The management team includes experienced professionals from various sectors, enhancing operational capabilities [66] - Future M&A activities will focus on filling gaps in service offerings rather than simply acquiring revenue [62] Important but Overlooked Content - The company has pruned underperforming markets to focus on scalable opportunities, which may lead to higher growth rates than previously indicated [52] - The emphasis on care gap closure and mobile health services is critical for improving patient outcomes and reducing overall healthcare costs [40][41] Conclusion - DocGo is strategically positioned in a fragmented healthcare market with a strong focus on mobile health and medical transport services, backed by a solid financial foundation and growth potential through innovative solutions and partnerships [63][66]

Medical transportation firm Modivcare filed for bankruptcy in an effort to shed $1.1 billion of debt, after federal health-care funding cuts complicated the company’s future finances https://t.co/MXy901E98D ...

Financial Data and Key Metrics Changes - The company announced a sale of the Blade passenger business to Joby Aviation for up to $125 million, which is expected to create long-term value for stakeholders [6][9] - Medical revenue grew 17.6% year-over-year to a record $45.1 million in Q2 2025, driven by new transplant center customers and increased demand [18][26] - Adjusted EBITDA margin for the medical segment rose to 13.4% in Q2 2025, compared to 11.4% in Q1 2025, but declined from 14.4% in Q2 2024 [18][20] Business Line Data and Key Metrics Changes - The medical business accounted for approximately 60% of revenue in 2024, up from 12% in 2020, and contributed about 85% of the segment's adjusted EBITDA [6][9] - The passenger business saw a 5.5% decrease in short-distance revenue year-over-year, primarily due to lower revenue in the US segment [20] - The passenger segment adjusted EBITDA tripled year-over-year from $800,000 to $2.4 million, driven by improved flight margins and lower SG&A expenses [22] Market Data and Key Metrics Changes - The company exited the Canadian market in August 2024, impacting short-distance revenue in the US [20] - European operations showed strong revenue growth due to realignment with local partners and operational changes [21] Company Strategy and Development Direction - The company aims to focus on its medical division as a standalone entity, which will be renamed Strata Critical Medical, emphasizing its growth potential in the medical sector [6][9] - A disciplined capital allocation strategy is planned, supported by approximately $200 million in cash from the passenger business sale [12][26] - The company is entering a long-term partnership with Joby Aviation to access eVTOL aircraft for medical use, enhancing its service offerings [15][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects of the medical business, expecting mid-teens revenue growth in the second half of 2025 [26] - The company anticipates improved fleet uptime and adjusted EBITDA margins in the medical segment, projecting margins of approximately 15% [26] - Management noted that the divestiture is expected to be neutral to adjusted EBITDA and free cash flow on a go-forward basis [25][26] Other Important Information - The company ended the quarter with no debt and $113.4 million in cash and short-term investments [25] - The financial impact of the divestiture is expected to be adjusted EBITDA and free cash flow neutral, supported by estimated corporate cost efficiencies of $7 million [10][25] Q&A Session Summary Question: What are the current priorities for capital allocation post-transaction? - Management highlighted opportunities in M&A and organic growth, emphasizing the need for capital to scale the business effectively [29][30] Question: Are there any operational impacts from the divestiture on the medical segment? - Management stated that the company is set up for success as a standalone entity and expects the partnership with Joby to add significant value [32][33] Question: Why was the passenger business sold now? - Management indicated that the market was discounting the value of the passenger business, and the divestiture allows for a clearer focus on the high-growth medical segment [37][38] Question: What is the growth outlook for the medical business? - Management expressed optimism about organic growth driven by new technologies and services, aiming for high teens adjusted EBITDA margins in the long term [41][43] Question: How is the business trending quarter to date? - Management reported strong performance in July, with no signs of seasonal slowdown yet [44] Question: What are the tax implications of the transaction? - Management noted that they have enough NOLs to offset capital gains from the divestiture, expecting minimal cash tax impact [46]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of ModivCare, Inc. related to misrepresentation of financial conditions and operational performance [1] Group 1: Legal Investigation - Kuehn Law is looking into whether ModivCare's insiders misrepresented or failed to disclose critical information regarding contracts in the non-emergency medical transportation (NEMT) segment [2] - The investigation focuses on claims that these misrepresentations led to a deterioration in the company's free cash flow and negatively impacted adjusted EBITDA due to contract renegotiations and pricing accommodations [2] Group 2: Financial Implications - The company reportedly faced insufficient liquidity as a result of the aforementioned issues, which raises concerns about its financial stability [2] - Positive statements made by the company regarding its business operations and future prospects were deemed materially misleading and lacked a reasonable basis [2]